Cargando…
Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals
OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD. STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication e...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713592/ https://www.ncbi.nlm.nih.gov/pubmed/31227785 http://dx.doi.org/10.1038/s41372-019-0415-9 |
_version_ | 1783446893618003968 |
---|---|
author | Bamat, Nicolas A. Kirpalani, Haresh Feudtner, Chris Jensen, Erik A. Laughon, Matthew M. Zhang, Huayan Monk, Heather M. Passarella, Molly Lorch, Scott A. |
author_facet | Bamat, Nicolas A. Kirpalani, Haresh Feudtner, Chris Jensen, Erik A. Laughon, Matthew M. Zhang, Huayan Monk, Heather M. Passarella, Molly Lorch, Scott A. |
author_sort | Bamat, Nicolas A. |
collection | PubMed |
description | OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD. STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use. RESULTS: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17– 45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22 – 50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD. CONCLUSIONS: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center. |
format | Online Article Text |
id | pubmed-6713592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-67135922019-12-21 Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals Bamat, Nicolas A. Kirpalani, Haresh Feudtner, Chris Jensen, Erik A. Laughon, Matthew M. Zhang, Huayan Monk, Heather M. Passarella, Molly Lorch, Scott A. J Perinatol Article OBJECTIVE: To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD. STUDY DESIGN: We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use. RESULTS: In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17– 45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22 – 50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD. CONCLUSIONS: Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center. 2019-06-21 2019-09 /pmc/articles/PMC6713592/ /pubmed/31227785 http://dx.doi.org/10.1038/s41372-019-0415-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Bamat, Nicolas A. Kirpalani, Haresh Feudtner, Chris Jensen, Erik A. Laughon, Matthew M. Zhang, Huayan Monk, Heather M. Passarella, Molly Lorch, Scott A. Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals |
title | Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals |
title_full | Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals |
title_fullStr | Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals |
title_full_unstemmed | Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals |
title_short | Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals |
title_sort | medication use in infants with severe bronchopulmonary dysplasia admitted to united states children’s hospitals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713592/ https://www.ncbi.nlm.nih.gov/pubmed/31227785 http://dx.doi.org/10.1038/s41372-019-0415-9 |
work_keys_str_mv | AT bamatnicolasa medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT kirpalaniharesh medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT feudtnerchris medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT jensenerika medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT laughonmatthewm medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT zhanghuayan medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT monkheatherm medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT passarellamolly medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals AT lorchscotta medicationuseininfantswithseverebronchopulmonarydysplasiaadmittedtounitedstateschildrenshospitals |